Akari Therapeutics Files 8-K on Operations
Ticker: AKTX · Form: 8-K · Filed: Apr 16, 2025 · CIK: 1541157
Sentiment: neutral
Topics: operations, financial-condition, filing
Related Tickers: AKTX
TL;DR
AKTX filed an 8-K on 4/16/25 detailing financial condition and results.
AI Summary
Akari Therapeutics Plc filed an 8-K on April 16, 2025, reporting on its results of operations and financial condition, and including financial statements and exhibits. The company, formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC, is incorporated in England and Wales and has its principal executive offices in Boston, MA.
Why It Matters
This filing provides an update on Akari Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing operational and financial updates, not indicating any immediate significant risks.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Celsus Therapeutics Plc (company) — Former company name
- Morria Biopharmaceuticals PLC (company) — Former company name
- April 16, 2025 (date) — Date of report
- 22 Boston Wharf Road FL 7 Boston, MA 02210 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Akari Therapeutics?
The primary purpose is to report on the company's results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
The report was filed on April 16, 2025.
What were Akari Therapeutics' previous names?
Akari Therapeutics was formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.
Where are Akari Therapeutics' principal executive offices located?
The principal executive offices are located at 22 Boston Wharf Road, FL 7, Boston, MA 02210.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2025 regarding Akari Therapeutics Plc (AKTX).